The genetic material from the donor makes up less than 1% of the baby born by using the experimental IVF technique.

Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision ...

Blood tests could pave the way for distinguishing between Alzheimer’s, Parkinson’s and some dementias, aiding early treatment for brain diseases.